Zobrazeno 1 - 10
of 2 832
pro vyhledávání: '"Favipiravir"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Telomerase enzyme prevents telomere shortening during division, having human telomerase reverse transcriptase (hTERT) as its catalytic subunit. Favipiravir (FAV), an RNA-dependent RNA polymerases inhibitor, shared structural similarity with
Externí odkaz:
https://doaj.org/article/d7ebd7cc718446f4bd5eda35829ce114
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 3, Pp 268-284 (2024)
INTRODUCTION. The risk of liver damage correlates with the severity of COVID-19. However, a growing number of studies have shown an association between liver function impairment and combinations of medicinal products used to treat COVID-19.AIM. The s
Externí odkaz:
https://doaj.org/article/908bb8ced2e34e8b9a371822385ab873
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract In this study, Density-functional theory/Time-dependent density-functional theory (DFT/TDDFT) and Molecular docking method was used to investigate the effect of methyl acetate, tetrahydrofuran and cyanobenzylidene substituents on the electro
Externí odkaz:
https://doaj.org/article/554c32380227470a83880011da4412fd
Autor:
S. Ya. Loginova, V. N. Schukina, S. V. Savenko, V. V. Rubtsov, S. V. Borisevich, D. L. Chizhov, G. L. Rusinov, E. V. Verbitskiy, V. N. Charushin, S. K. Kotovskaya, V. L. Rusinov
Publikováno v:
Антибиотики и Химиотерапия, Vol 69, Iss 3-4, Pp 21-30 (2024)
Background. The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, originated in Wuhan, China, has claimed millions of lives around the world. In this regard, the search for effective drugs, including the repurposing of existing ones, has becom
Externí odkaz:
https://doaj.org/article/9660279325d74f5aa1e3941ad160ac4b
Publikováno v:
JPSCR: Journal of Pharmaceutical Science and Clinical Research, Vol 9, Iss 1, Pp 45-61 (2024)
COVID-19 is an acute respiratory disease resulting from the infection of SARS-COV-2 viruses and causes high morbidity, which requires appropriate treatment targets. Favipiravir is an antiviral that selectively inhibits RNA-dependent RNA polymerase (R
Externí odkaz:
https://doaj.org/article/c1369a134d394a8cbb24d395c7ef289f
Autor:
Chavalertsakul K, Sutherasan Y, Petnak T, Thammavaranucupt K, Kirdlarp S, Boonsarngsuk V, Sungkanuparph S
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 2163-2175 (2024)
Karuna Chavalertsakul,1 Yuda Sutherasan,1 Tananchai Petnak,1 Kanin Thammavaranucupt,2 Suppachok Kirdlarp,2 Viboon Boonsarngsuk,1 Somnuek Sungkanuparph2 1Division of Pulmonary and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Me
Externí odkaz:
https://doaj.org/article/98a66926e4bf4c1fa748944149735e54
Autor:
Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Panisadee Avirutnan, Kunlakanya Jitobaom, Prasert Auewarakul
Publikováno v:
Journal of Infection and Public Health, Vol 17, Iss 5, Pp 897-905 (2024)
Background: The efficacy of the viral clearance and clinical outcomes of favipiravir (FPV) in outpatients being treated for coronavirus disease 2019 (COVID-19) is unclear. Ivermectin (IVM), niclosamide (NCL), and FPV demonstrated synergistic effects
Externí odkaz:
https://doaj.org/article/60ae10a978e145a6b07adecdb6ef3723
Autor:
T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, A. V. Taganov, I. E. Shohin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 281-290 (2024)
Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses antiviral properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). The new drug Areplivir® Zin
Externí odkaz:
https://doaj.org/article/81e416e4f0bc4b9390c264abd2533f7e
Autor:
T. N. Komarov, K. K. Karnakova, N. S. Bagaeva, O. A. Archakova, M. O. Popova, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, I. E. Shohin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 272-280 (2024)
Introduction. COVID-19 (Coronavirus disease 2019) almost 4 years after he start of the pandemic is still a significant public health problem. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) that causes COVID-19 continues to mutate and sp
Externí odkaz:
https://doaj.org/article/e107ec5b3e7946f48b26c0a04f267d34
Autor:
Oskar Yuda Daud, Robert Sinurat
Publikováno v:
Althea Medical Journal, Vol 11, Iss 1, Pp 1-6 (2024)
Background: COVID-19 patients who come to the emergency room often suffer from stroke. This study aimed to examine clinical symptoms and treatment outcomes of COVID-19 patients with stroke. Methods: This study was a retrospective study using seconda
Externí odkaz:
https://doaj.org/article/b435de9243144acab92be04677d62450